Board of Directors
Roger Pomerantz, M.D. President, Chief Executive Officer, and Chairman of the Board of Directors
Roger Pomerantz is the President, Chief Executive Officer, and Chairman of the Board of Directors of Seres Therapeutics, Inc. ("Seres"). Prior to joining Seres, Dr. Pomerantz was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc., where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Dr. Pomerantz was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. Dr. Pomerantz earned his B.A. in biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his internal medicine internship and residency training, and his subspecialty clinical and research training in infectious diseases and virology at the Massachusetts General Hospital of Harvard Medical School. His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology (MIT), in the laboratory of Nobel Laureate Dr. David Baltimore. Dr. Pomerantz also served as the Chief Resident at the Massachusetts General Hospital. Following his medical-scientist training, he was an Endowed, Tenured Professor of Medicine and Molecular Pharmacology and Chairman of the Infectious Diseases Department of Thomas Jefferson University in Philadelphia. Dr. Pomerantz is an internationally recognized expert in HIV molecular pathogenesis and latency. He has developed ten approved infectious disease drugs in important diseases including HIV, HCV, tuberculosis, and Clostridium difficile infection.
Noubar Afeyan, Ph.D. Co-Founder Seres Therapeutics; Managing Partner and CEO, Flagship Pioneering
Noubar Afeyan is Managing Partner and CEO of Flagship Pioneering. He is a recognized technologist and entrepreneur. He has more than 25 years of experience as an inventor, entrepreneur, CEO, and venture capitalist. Dr. Afeyan has co-founded and helped build numerous successful life sciences companies and technology startups. He was founder and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Dr. Afeyan was also a founder, director, and investor in Chemgenetics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), and Adnexus Therapeutics (acquired by Bristol-Myers Squibb). Dr. Afeyan currently serves on a number of public and private company boards including Affinnova, BG Medicine, Pronutria, Joule Unlimited, and Moderna Therapeutics. He earned his Ph.D. in biochemical engineering from the Massachusetts Institute of Technology (MIT) in 1987.
Dennis Ausiello, M.D. Jackson Professor of Clinical Medicine at Harvard Medical School; Chair of Medicine, Emeritus at Massachusetts General Hospital
Dennis A. Ausiello is the Jackson Distinguished Professor of Clinical Medicine and Director, Emeritus of the MD/PhD Program at Harvard Medical School. He is also Chair of Medicine, Emeritus, and Director of the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital. He received his undergraduate degree from Harvard College and his medical degree from the University of Pennsylvania. Dr. Ausiello has made substantial contributions to the study of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters, and textbooks, and served as an editor of Cecil's Textbook of Medicine.
Grégory Behar CEO, Nestlé Health Science S.A.
Grégory Behar has served as a member of our board of directors since December 2014. Mr. Behar has served as Chief Executive Officer of Nestlé Health Science S.A., a health sciences company, since October 2014. From July 2011 to July 2014, Mr. Behar was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. (USA), a pharmaceutical company. From 2010 to July 2011, Mr. Behar was Corporate Vice President Region NECAR (North European Union, Canada and Australasia) for Boehringer-Ingelheim GmbH, a pharmaceutical company. Mr. Behar received his B.S. from the University of California, Los Angeles, a M.S. in Mechanical Engineering and Manufacturing from EPFL in Switzerland and an MBA from INSEAD in France. We believe that Mr. Behar is qualified to serve on our board of directors because of his extensive business experience in the health sciences and pharmaceutical industries.
Kurt Graves Chairman, President and CEO, Intarcia Therapeutics, Inc.
Mr. Graves has been Chairman, President and CEO of Intarcia since April 2012, having previously served solely as Chairman of the company since August 2010 and as Acting CEO since October 2011. He is a global industry leader with more than twenty years of U.S. and global general management experience at top-tier U.S. and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies; at Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals. Prior to his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Prior to Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. In addition to Intarcia, Mr. Graves serves as Chairman of the Board of Radius therapeutics (RDUS), and as a Director at Achillion Pharmaceuticals (ACHN), Seres Therapeutics (MCRB). Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.
Lorence Kim, M.D. Chief Financial Officer, Moderna
Lorence Kim is the CFO of Moderna Therapeutics, a pioneer in messenger RNA therapeutics. Prior to joining Moderna, he was a managing director and co-head of the U.S. biotechnology investment banking effort at Goldman Sachs. He joined Goldman Sachs in 1999 as a summer associate and was named managing director in 2008. As a member of the Healthcare Investment Banking Group for nearly 14 years, Dr. Kim’s responsibilities included corporate finance and mergers and acquisitions for the pharmaceutical and biotechnology industries. Prior to joining Goldman Sachs, Dr. Kim worked in various medical research and consulting positions concurrent with his graduate studies. Dr. Kim earned his B.A. in biochemical sciences in 1995. He earned his M.B.A. in health care management as a Palmer Scholar from the Wharton School of the University of Pennsylvania in 2000, and his M.D. from the University of Pennsylvania’s School of Medicine in 2000.
Peter Barton Hutt Senior Counsel, Covington & Burling, LLP
Peter Barton Hutt is a senior counsel in the Washington, D.C., law firm of Covington & Burling specializing in food and drug law. Prior to joining Covington & Burling, Mr. Hutt served as Chief Counsel for the Food and Drug Administration from 1971 to 1975. He has been a member of the Institute of Medicine since it was founded in 1971, and he served on the Panel on the Administrative Restructuring of the National Institutes of Health. Mr. Hutt serves on academic and venture capital advisory boards, and the boards of numerous startup biotechnology companies. He has been named by the National Law Journal as one of the 40 best health care lawyers in the United States. Mr. Hutt recieved his B.A. from Yale University, his L.L.B. from Harvard Univeristy and his L.L.M from New York University.
Richard Kender Former Senior Vice President of Business Development and Corporate Licensing, Merck
Richard Kender is a retired executive with 35 years of experience in the pharmaceutical industry, most recently as Senior Vice President of Business Development and Corporate Licensing at Merck. Mr. Kender joined Merck in 1978 and spent his entire professional career, until his retirement in 2013, at the company in various corporate roles. At Merck, Mr. Kender was involved in more than 100 transactions of various size and type. He serves on the Board of Directors of INC Research Holdings, Inc., and has served on the Board of Directors of FoxHollow Technologies Inc. and EV3 Inc. Mr. Kender has also served on the Board of Trustees of BioNJ. Mr. Kender earned his B.S. in accounting from Villanova University and his M.B.A. from Fairleigh Dickinson University.